Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Ra Capital Management Initiates Stake in Furiex Pharmaceuticals Inc (FURX) After the Stock Jumped

Peter Kolchinsky‘s Ra Capital Management, has just disclosed initiating a 7.2% stake in Furiex Pharmaceuticals Inc (NASDAQ:FURX). The position amasses 750,000 shares and is passive by nature. The value of the holding amounts to $84.23 million, at the current price of the company’s stock.

Peter Kolchinsky

Furiex Pharmaceuticals Inc (NASDAQ:FURX) went on the radars just yesterday, when it’s stock jumped by a whooping 130%. In our newsletter back in December, we recommended to buy shares of Furiex, based on the recommendation from Michael Castor.

The significant boost gained by Furiex Pharmaceuticals Inc (NASDAQ:FURX)’s stock came amid positive results regarding the company’s two pivotal Phase III clinical trials, which evaluated the safety of eluxadoline in the cure of diarrhea-predominant irritable bowel syndrom. The results of the studies met the endpoints agreed by the U.S. Food and Drug Administration and the European Medicines Agency.

Even though Ra Capital acquired shares of Furiex Pharmaceuticals Inc (NASDAQ:FURX) after the price of the stock surged, we can assume that the fund still expects it to gain some ground. Aside from Ra, which now holds a significant stake in Furiex, another shareholder is Chuck Royce‘s Royce & Associates, which in the third quarter of last year held 232,900 shares of the company.

Ra Capital is a fund focused on the healthcare sector, investing in companies with perspectives to deliver promising drugs and technologies. Last month, the fund reported selling 300,000 shares of Derma Sciences Inc (NASDAQ:DSCI), reducing its stake to 1.69 million shares. Also, the fund has been bullish on Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) raising the stake to 23.4 million shares.

Disclosure: none

Recommended Reading:

Deerfield Management Discloses Stake in Post-IPO Auspex Pharmaceuticals Inc (ASPX)

Deerfield Management & Brookside Capital Revealed Significant Stakes in Newly Public Dicerna Pharmaceuticals Inc (DRNA)

Sanford J. Colen’s Apex Capital’s Top Picks Include Netflix, Inc. (NFLX) & eBay Inc (EBAY) Among Others

Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!